H.C. Wainwright Remains a Buy on Sana Biotechnology (SANA)
H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on Sana Biotechnology (SANA) with a $7.00 price target. This recommendation is supported by a Strong Buy consensus from other analysts, with an average price target of $8.00. The company recently reported a quarterly GAAP net loss of $63.64 million, an improvement from $93.8 million in the previous year.
Sana Biotechnology, Inc. (SANA) Investor Outlook: A Biotech Player with a 171.89% Upside Potential
Sana Biotechnology, Inc. (SANA) is a biotech company focused on cell-based therapies with a significant potential upside of 171.89% according to analysts. Despite facing typical biotech challenges like deferred profitability and a negative return on equity, Sana is advancing a robust pipeline, including a Phase 1 clinical trial for type 1 diabetes. The company's strategic collaborations and positive free cash flow offer financial flexibility as it pursues its growth-oriented strategy.
Sana Biotechnology at citigroup’s biopharma back to school summit 2026: diabetes push
Sana Biotechnology (SANA) presented its strategy at Citigroup’s Biopharma Back to School Summit 2026, focusing on its SC451 type 1 diabetes program, which is nearing an IND filing, and its SG293 in vivo CAR T program, delayed in China. The company reported $160 million in cash, sufficient for about a year of operations, and addressed manufacturing challenges and the significant unmet need in type 1 diabetes, highlighting the potential for a functional cure. Despite a stock decline and overvaluation concerns, analysts see substantial upside potential for SANA.
Sana Biotechnology to Present at September 2026 Investor Conferences
Sana Biotechnology, Inc. announced its participation in four investor conferences in September 2026. The company will present business overviews and updates at the Wells Fargo Healthcare Conference, Citi's Biopharma Back-to-School Conference, the Morgan Stanley 24th Annual Global Healthcare Conference, and the HC Wainwright 28th Annual Global Investment Conference. Webcasts of these presentations will be available on Sana's Investor Relations page.
Sana Biotechnology to Present at September 2026 Investor Conferences
Sana Biotechnology, Inc. (NASDAQ: SANA) announced that it will present at four investor conferences in September 2026. The company will provide a business overview and update at the Wells Fargo Healthcare Conference, Citi’s Biopharma Back-to-School Conference, the Morgan Stanley Global Healthcare Conference, and the HC Wainwright Global Investment Conference. Webcasts of these presentations will be available on Sana's investor relations website.
Is Sana Biotechnology (SANA) Turning Cost Discipline Into a More Durable Investment Narrative?
Sana Biotechnology (SANA) reported a narrower net loss and reduced loss per share for Q2 2026, indicating improved cost control and financial efficiency. While these results strengthen the investment case by easing near-term cash burn worries, the company still faces challenges including a short cash runway and skepticism regarding its share price valuation. Investors are encouraged to consider multiple perspectives and risks, including the need for clinical progress in its cell and gene engineering programs.
Is Sana Biotechnology (SANA) Turning Cost Discipline Into a More Durable Investment Narrative?
Sana Biotechnology (SANA) reported a narrower net loss and reduced loss per share for Q2 2026, indicating improved cost discipline. While this strengthens the investment case by easing concerns about cash burn, the fundamental drivers remain clinical progress in its core programs. Investor opinions on the company's valuation vary widely, highlighting a need for careful consideration given the short cash runway and ongoing losses.
Will Sana Biotechnology (NASDAQ:SANA) Spend Its Cash Wisely?
This article examines Sana Biotechnology's financial health, specifically its cash reserves and burn rate, to assess its ability to fund operations. It highlights that the company has sufficient cash for over two years at its current burn rate but warns that investors should closely monitor its future cash usage and potential capital raises. The analysis suggests that while the current cash position is strong, the burn rate is high, necessitating careful management.
Sana Biotechnology, Inc. (NASDAQ:SANA) Given Average Rating of "Moderate Buy" by Analysts
Sana Biotechnology, Inc. (NASDAQ:SANA) has received an average "Moderate Buy" rating from nine analysts, with seven buy ratings, one hold, and one sell. The average 12-month price target for the stock is $9.33, significantly higher than its recent price of $3.74. Institutional investors hold a substantial 88.23% of Sana's shares, and the company recently reported a quarterly loss of $0.13 per share, beating analyst estimates.
Is Sana Biotechnology (SANA) Turning Cost Discipline Into a More Durable Investment Narrative?
Sana Biotechnology reported a narrower net loss and reduced loss per share for Q2 2026 and the first half of the year, signaling improved cost controls and financial efficiency. While this strengthens the investment case by easing concerns about cash burn, the fundamental drivers remain clinical progress and partnerships. Investors should still consider the short cash runway and "going concern" doubts.
Is Sana Biotechnology (SANA) Turning Cost Discipline Into a More Durable Investment Narrative?
Sana Biotechnology reported a narrower net loss and reduced loss per share for Q2 2026, suggesting improved cost management. While this strengthens its investment narrative by easing concerns about cash burn, investors should also consider the short cash runway and "going concern" doubts. The company's long-term success still hinges on clinical progress and its cell and gene engineering platforms.
Sana Biotechnology (NASDAQ:SANA) Stock Price Down 6.2% - Time to Sell?
Sana Biotechnology's stock price dropped 6.2% to $3.845, with trading volume significantly lower than average. Despite the dip, analyst sentiment is mixed but largely positive, with a "Moderate Buy" consensus rating and an average price target of $9.33, well above its current price. The clinical-stage biotech company also beat its quarterly earnings expectations, reporting a loss of $0.13 per share against an estimated $0.15 loss.
Can Sana Biotechnology (SANA) Justify Its Valuation On Narrower Losses?
Sana Biotechnology (SANA) recently reported narrower net losses for Q2 and H1 2026, leading to a recent positive shift in share performance despite longer-term declines. The company trades at a Price-to-Book ratio of 7x, significantly higher than the industry and peer averages, indicating an expensive valuation. While recent performance suggests some investor optimism, ongoing net losses and clinical trial uncertainties pose risks to its current premium valuation.
Can Sana Biotechnology (SANA) Justify Its Valuation On Narrower Losses?
Sana Biotechnology (SANA) recently reported narrower net losses for Q2 and H1 2026, leading to a recent positive shift in share price momentum. However, the company's Price-to-Book (P/B) ratio of 7x is significantly higher than the industry average, suggesting an overvalued status. Investors are cautioned to consider the ongoing net losses and clinical trial uncertainties despite the improved earnings.
Alphabet Inc. Makes New $9.82 Million Investment in Sana Biotechnology, Inc. $SANA
Alphabet Inc. has acquired a new stake of 2,812,500 shares in Sana Biotechnology, Inc. (NASDAQ:SANA) valued at approximately $9.82 million during the second quarter, making it their 22nd largest position. Other institutional investors have also adjusted their holdings in Sana Biotechnology. The company currently holds a "Moderate Buy" rating with a consensus price target of $9.33 from analysts.
ARCH venture funds disclose 15%+ Sana Biotechnology (SANA) ownership in updated filing
ARCH venture funds and related entities, along with several individual managers, have reported an updated collective beneficial ownership of 15.3% in Sana Biotechnology (SANA) common stock as of June 30, 2026. This amounts to 45,860,681 shares based on 299,360,637 shares outstanding. Robert Nelsen, a manager, holds an even higher stake of 15.4% when accounting for his vested options, RSUs, and family trust holdings.
Sana Biotechnology | SCHEDULE 13G/A: Others
This article is a Schedule 13G/A filing for Sana Biotechnology. It indicates an amendment to a previous filing, typically related to significant ownership of the company's stock by an institutional investor or beneficial owner. This is a standard regulatory disclosure.
Sana Biotechnology (NASDAQ:SANA) Shares Down 5.3% - Should You Sell?
Sana Biotechnology (NASDAQ:SANA) shares dropped 5.3% to $3.4750 on Friday, with trading volume significantly below average. Despite the dip, analyst sentiment is mixed but leans positive, with an average target price of $9.50, although one analyst recently downgraded the stock to "Sell." The company reported a narrower-than-expected quarterly loss of $0.13 per share and continues its focus on developing engineered-cell therapies for cancer and genetic diseases.
Sana Biotechnology, Inc. Stock 12‑Month Price Target Cut to $9.38, Implies 155% Upside
Sana Biotechnology, Inc.'s average 12-month price target has been reduced slightly from $9.5 to $9.38 by 8 analysts, with individual forecasts ranging from $6 to $16 per share. Despite the cut, the new target still suggests a significant 155% potential upside based on the Aug. 13 closing price. The consensus rating from 10 covering analysts remains a "Buy," with 9 analysts recommending Buy and 1 recommending Hold.
BofA Securities Adjusts Sana Biotechnology Price Target to $6 From $7
BofA Securities has lowered its price target for Sana Biotechnology (SANA) to $6 from $7, as reported on August 14, 2026. This adjustment follows other recent news for the company, including its Q2 adjusted loss narrowing and its removal from several Russell Value Benchmarks in late June. The article also provides a company profile, financial data, analyst consensus, and a list of recent news related to Sana Biotechnology.
HC Wainwright Has Pessimistic Outlook of SANA Q3 Earnings
HC Wainwright has lowered its Q3 2026 earnings forecast for Sana Biotechnology (NASDAQ:SANA) to a loss of $0.14 per share, anticipating continued losses through future fiscal years. Despite this, Sana's last quarterly loss of $0.13 per share exceeded analyst expectations. The stock currently holds a "Moderate Buy" consensus rating from analysts, with institutional investors owning a significant portion of its shares.
Sana Biotechnology (SANA) Is Up 13.5% After Narrower Losses And Mayo Clinic Equity Deal - What's Changed
Sana Biotechnology (SANA) saw its stock rise by 13.5% after reporting narrower losses in Q2 2026 and announcing a significant collaboration with the Mayo Clinic, which includes a $25 million equity investment. The company also made progress in its clinical trial programs and released encouraging data for its UP421 cell therapy. While these developments provide positive catalysts, the company still faces challenges such as zero revenue, ongoing losses, and a rich price-to-book multiple.
Sana Biotechnology (SANA) Is Up 13.5% After Narrower Losses And Mayo Clinic Equity Deal - What's Changed
Sana Biotechnology (SANA) reported narrower losses in Q2 2026 and announced a US$25 million equity deal with the Mayo Clinic, contributing to a 13.5% stock increase. The company also made progress in its clinical programs and unveiled promising data for its UP421 cell therapy. Despite these positive developments, the article highlights ongoing financial risks due to zero revenue, continuous losses, and an inflated share price compared to its estimated value.
Sana Biotechnology | 10-Q: Quarterly report
This document is a 10-Q Quarterly Report filed by Sana Biotechnology. It provides a formal financial and operational update for the quarter.
Sana Biotechnology Q2 Results: Adj. EPS beats estimate
Sana Biotechnology reported stronger-than-expected Q2 2026 results, with non-GAAP EPS of $(0.13) surpassing analyst estimates. The company secured $93.3 million in new funding, increasing its cash reserves to $160.5 million and extending its financial runway until mid-2027. This financial stability supports the advancement of its lead programs, SC451 and SG293, towards Phase 1/2 clinical trials this year, alongside a new strategic partnership and investment from Mayo Clinic.
Sana Biotechnology (NASDAQ:SANA) Issues Earnings Results
Sana Biotechnology (NASDAQ:SANA) reported a quarterly loss of $0.13 per share, surpassing the consensus estimate of a $0.15 loss. Following the announcement, SANA shares increased by 2.6% to $3.61. The company holds a "Moderate Buy" consensus rating from analysts with an average price target of $9.50, and institutional investors own 88.23% of its stock.
Earnings Flash (SANA) Sana Biotechnology, Inc. Posts Q2 Adjusted Loss $0.13 per Share, vs. FactSet Est of $-0.12
Sana Biotechnology, Inc. (SANA) reported a Q2 adjusted loss of $0.0.13 per share, which was narrower than the FactSet estimate of a $0.12 loss per share. The company focuses on developing engineered cells as medicines for therapeutic areas such as type 1 diabetes, oncology, and autoimmune diseases. Sana Biotechnology's stock, trading on Nasdaq, showed a 5-day change of +2.56% and a year-to-date change of -11.30% as of August 10, 2026.
Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates
Sana Biotechnology reported its Q2 2026 financial results, highlighting significant progress in its clinical programs for SC451 in type 1 diabetes and SG293 in non-Hodgkin lymphoma, with both expected to start clinical trials this year. The company also announced a follow-on publication in The New England Journal of Medicine for its UP421 hypoimmune-modified islet cell transplantation and a strategic collaboration with Mayo Clinic. Sana ended the quarter with $160.5 million in cash, projecting a runway into mid-2027.
Sana Biotechnology faces earnings test as CAR-T program advances
Sana Biotechnology Inc. is set to report its second-quarter results on Monday, with analysts expecting a narrower loss of 15 cents per share and no revenue. Investors will be closely watching for updates on its in vivo CAR-T platform, specifically SG293, and its stem cell-derived islet cell therapy SC451, as well as the company's cash burn and financing plans. The stock has a "strong-buy" rating from Wall Street, with an implied upside of 143% from its current trading price.
Sana Biotechnology Inc (SANA) Earnings Forecast: Future EPS & Revenue Growth Estimates
Sana Biotechnology Inc (SANA) has a target price of USD 7.00, with analysts forecasting a potential upside of 151.36%. Based on ratings from 9 analysts, the consensus for SANA stock is a "Buy." The company's EPS for the previous quarter was USD -0.21, and the next quarter is expected at USD -0.15.
Sana Biotechnology (SANA) Projected to Release Earnings on Monday
Sana Biotechnology (SANA) is expected to report its Q2 2026 earnings on Monday, August 10th, with analysts projecting a loss of $0.1469 per share. The company's shares opened at $3.08, and its market capitalization is approximately $858 million. Analyst sentiment is mixed but leans positive, with an average price target of $9.50 and institutional investors owning 88.23% of the stock.
Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Halper Sadeh LLC, an investor rights law firm, is investigating whether officers and directors of Sana Biotechnology, Inc. (NASDAQ: SANA) breached their fiduciary duties to shareholders. The firm encourages long-term Sana shareholders to contact them to discuss legal options, including seeking corporate governance reforms or the return of funds to the company. They operate on a contingent fee basis, meaning shareholders would not be responsible for out-of-pocket legal fees.
Sana Biotechnology Inc (SANA) Cash Flow
This article provides a detailed cash flow statement for Sana Biotechnology Inc (SANA), including quarterly and annual data for operating, investing, and financing activities. It presents key financial metrics such as net income, capital expenditures, and free cash flow, alongside year-over-year percentage changes. The article also includes a FAQ section defining different types of cash flow and their significance for investors.
SANA|Sana Biotechnology Inc|Price:3.285|Chg%:+0.105
This article provides a detailed financial overview of Sana Biotechnology Inc (SANA), including its stock price, market cap, and key financial indicators. It presents current and historical data for income statements, balance sheets, and cash flow statements, along with recent earnings reports and analyst ratings. The report highlights the company's EPS, net profit, assets, liabilities, and equity, offering insights into its financial health over various quarters and fiscal years.
Sana Biotechnology Inc (SANA) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Sana Biotechnology Inc (SANA), detailing its support, resistance, indicators, and moving averages. It covers various technical indicators like MACD, RSI, KDJ, and ATR, along with moving averages (MA5 to MA200), to offer a "Neutral" signal for the stock based on current trends. The analysis indicates a mixed performance from individual indicators but leans towards buy signals from most moving averages.
Levi & Korsinsky Notifies Sana Biotechnology, Inc. (SANA) Investors - Lead Plaintiff Deadline on May 20, 2025
Levi & Korsinsky is notifying investors of Sana Biotechnology, Inc. (NASDAQ:SANA) who suffered losses that a lead plaintiff deadline is approaching on May 20, 2025. The class action securities lawsuit alleges that Sana Biotechnology made false and misleading statements about its financial capacity, the promise of certain product candidates (SC291, SC379, and SG299), and the likelihood of funding reductions or discontinuations. Investors affected between March 17, 2023, and November 4, 2024, are encouraged to seek information regarding potential recovery.
Sana Biotechnology, Inc. (SANA) Stock Analysis: Exploring a 167% Potential Upside in the Biotech Arena
Sana Biotechnology, Inc. (SANA) is a key player in the biotechnology sector, focusing on cell engineering for unmet medical needs like type 1 diabetes and oncology. Despite current unprofitability and negative financial metrics common in R&D-heavy biotech, analysts are optimistic, assigning 8 buy ratings and a significant potential upside of 167.02% from its current trading price of $3.21 to an average target price of $8.57. Strategic collaborations and an innovative product pipeline, such as UP421 and SC451, underscore its growth potential, making it an intriguing consideration for investors in the high-growth healthcare sector, despite the inherent volatility.
Sana Biotechnology Inc SANA Price:3.215 Chg%:+0.095
This article provides a detailed financial overview of Sana Biotechnology Inc (SANA), including its current stock price, market capitalization, key figures, and year-to-date performance. It highlights analyst ratings, which show a strong "Buy" consensus with a significant upside, and lists major shareholders. The company's focus on engineered cell therapies for diseases like type 1 diabetes and cancer is also described.
Sana Biotechnology (SANA) Jefferies Global Healthcare Conference 2026 Summary
Sana Biotechnology presented at the Jefferies Global Healthcare Conference 2026, highlighting their hypoimmune allogeneic cell therapy and in vivo gene delivery platforms, both nearing clinical trials. The company aims for a functional cure for type 1 diabetes, focusing on immune evasion and insulin independence. Key developments include an IND filing and Phase I trial for type 1 diabetes targeted for 2026, with anticipated rapid clinical progression and ongoing regulatory and manufacturing advancements.
Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1 Diabetes
Sana Biotechnology announced a follow-on publication in The New England Journal of Medicine (NEJM) detailing 14-month follow-up data from an investigator-sponsored study of UP421, a hypoimmune-modified islet cell therapy for Type 1 Diabetes. The data reinforces that HIP-modified cells are safe, evade immune detection, and continue to produce insulin without immunosuppression. Sana expects to file an Investigational New Drug (IND) application for SC451, a stem cell-derived therapy, and initiate a Phase 1/2 trial this year, aiming for a one-time treatment that achieves long-term normal blood glucose without insulin or immunosuppression.
New Publication: Sana’s Gene-Edited Islets Continue to Make Insulin
A new publication details the ongoing insulin production in a type 1 diabetes patient treated with Sana Biotechnology’s gene-edited islets, 14 months post-transplant and without immunosuppressants. This first-in-human study shows promising safety and functionality, with the hypoimmune islets evading immune attack. Breakthrough T1D supports this research through Project ACT and the T1D Fund, aiming to accelerate scalable cell therapies for T1D without the need for long-term immune suppression.
Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1 Diabetes
Sana Biotechnology announced a follow-on publication in The New England Journal of Medicine (NEJM) highlighting 14-month efficacy data from an investigator-sponsored study of UP421, a hypoimmune-modified islet cell therapy. The study showed that this therapy has the potential to treat type 1 diabetes without immunosuppression by demonstrating the safety, immune evasion, survival, and long-term function of the modified cells. Sana expects to file an IND application and initiate a Phase 1/2 trial for SC451, a similar stem cell-derived therapy, as early as this year, aiming for long-term normal blood glucose without insulin therapy or immunosuppression.
Sana Biotechnology (SANA) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary
Sana Biotechnology presented a summary of its 43rd Annual J.P. Morgan Healthcare Conference 2025 appearance, highlighting key scientific advancements and clinical data, particularly the successful transplantation of gene-edited allogeneic islet cells in a type 1 diabetes patient without immunosuppression. The company also discussed the expansion of its hypoimmune (HIP) platform to other autoimmune diseases and blood cancers, and progress in manufacturing for scalable production. While significant progress has been made, challenges remain in manufacturing scale-up and creating GMP-compliant master cell banks for some programs.
Sana Biotechnology (SANA) H.C. Wainwright 27th Annual Global Investment Conference summary
Sana Biotechnology presented at the H.C. Wainwright 27th Annual Global Investment Conference, highlighting its Hypoimmune and Fusogen technology platforms. The company shared positive proof-of-concept data for its type 1 diabetes program, demonstrating insulin production without immunosuppression, and provided updates on its allogeneic and in vivo CAR T programs with upcoming clinical milestones. The summary covers the company's progress in gene-edited cell therapies for autoimmune diseases, blood cancers, and type 1 diabetes.
Sana Biotechnology (SANA) Morgan Stanley 23rd Annual Global Healthcare Conference summary
Sana Biotechnology (SANA) presented at the Morgan Stanley 23rd Annual Global Healthcare Conference, outlining its strategic vision to revolutionize medicine through gene and cell-based therapies, specifically targeting allogeneic transplant rejection and precise genetic repair. The company highlighted progress in its type 1 diabetes therapy, SC451, which aims for a curative, immunosuppression-free treatment, with an IND filing planned for the next year. Sana also detailed its clinical and regulatory strategy, emphasizing constructive interactions with the FDA and plans to expand trials to broader patient populations.
Sana Biotechnology (SANA) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary
Sana Biotechnology presented key scientific advances and clinical data at the 43rd Annual J.P. Morgan Healthcare Conference 2025, highlighting the first successful transplant of gene-edited allogeneic islet cells in a type 1 diabetes patient without immunosuppression. The company's hypoimmune (HIP) platform shows promise for autoimmune diseases and blood cancers, with ongoing clinical trials. Despite progress in manufacturing, challenges remain in creating GMP-compliant cell banks and scaling production for broad patient access.
Sana Biotechnology (SANA) Is Up 18.1% After Removal From Key Russell Value Indexes - What's Changed
Sana Biotechnology (SANA) was recently removed from several Russell value benchmarks, including the Russell 3000 Value and Russell 2000 Value indexes. This removal impacts how index funds and institutional investors view the stock, but it doesn't change the company's scientific or operational milestones. Investors need to focus on funding risk due to the company's lack of revenue and persistent losses, with a valuation report suggesting Sana Biotechnology might be overvalued.
Sana Biotech heads to EASD with diabetes cell therapy update
Sana Biotechnology will present clinical findings from its first-in-human study of UP421 at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026. This experimental cell therapy is designed to make transplanted insulin-producing cells "hidden" from the immune system, eliminating the need for lifelong immunosuppressive drugs in Type 1 diabetes patients. The company's Hypoimmune Platform (HIP) engineers cells to avoid immune rejection, and early results show transplanted cells surviving and producing insulin for 14 months without immunosuppression, even when implanted in a forearm muscle.
Sana Biotechnology (SANA) Bank of America Global Healthcare Conference 2026 Summary
Sana Biotechnology (SANA) delivered a summary at the Bank of America Global Healthcare Conference 2026, highlighting its dual strategic focus on engineering cells both ex vivo (for cell replacement in Type 1 diabetes) and in vivo (for cell repair/signaling change in CAR-T therapy). The company detailed the progress of its Type 1 diabetes program (SC451), including a successful proof of concept and an upcoming IND filing. They also discussed their manufacturing advancements, partnership with Mayo Clinic, and their strategy within the competitive landscape.
Sana Biotechnology | 4: Statement of changes in beneficial ownership of securities-Director Bishop Hans Edgar
This document from Sana Biotechnology details a Statement of changes in beneficial ownership of securities for Director Bishop Hans Edgar. The filing is a routine disclosure of insider transactions as required by the SEC.
